{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:20:33Z","timestamp":1783351233073,"version":"3.54.6"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.mehy.2019.02.051","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T22:36:37Z","timestamp":1551479797000},"page":"137-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Prolactin and Prolactin-inducible protein (PIP) in the pathogenesis of primary acquired nasolacrimal duct obstruction (PANDO)"],"prefix":"10.1016","volume":"125","author":[{"given":"Mohammad Javed","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Paulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2019.02.051_b0005","doi-asserted-by":"crossref","DOI":"10.1097\/IOP.0000000000001310","article-title":"Etiopathogenesis of primary acquired nasolacrimal duct obstruction (PANDO): what we know and what we need to know","author":"Ali","year":"2019","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.mehy.2019.02.051_b0010","series-title":"Principles and Practice of Lacrimal Surgery","first-page":"163","article-title":"Primary acquired nasolacrimal duct obstruction (PANDO) and secondary acquired lacrimal duct obstruction (SALDO)","author":"Kamal","year":"2018"},{"key":"10.1016\/j.mehy.2019.02.051_b0015","doi-asserted-by":"crossref","DOI":"10.1097\/IOP.0000000000001257","article-title":"The incidence of lacrimal drainage disorders across a tertiary eye care network: customization of an indigenously developed electronic medical record system \u2013 eyeSmart","author":"Das","year":"2018","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.mehy.2019.02.051_b0020","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0161-6420(01)00946-0","article-title":"New insights into the pathophysiology of primary acquired dacryostenosis","volume":"108","author":"Paulsen","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mehy.2019.02.051_b0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0161-6420(02)01442-2","article-title":"Loss of tear duct-associated lymphoid tissue in association with scarring of symptomatic dacryostenosis","volume":"110","author":"Paulsen","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mehy.2019.02.051_b0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/IOP.0000000000000962","article-title":"Qualitative hormonal profiling of the lacrimal drainage system: potential insights into the etiopathogenesis of primary acquired nasolacrimal duct obstruction","volume":"33","author":"Ali","year":"2017","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.mehy.2019.02.051_b0035","doi-asserted-by":"crossref","DOI":"10.1080\/01676830.2018.1514640","article-title":"Soluble glycoproteins of the lacrimal sac: role in defense with special reference to prolactin-inducible protein","author":"Ali","year":"2018","journal-title":"Orbit"},{"key":"10.1016\/j.mehy.2019.02.051_b0040","first-page":"3","article-title":"Prolactin biology and laboratory measurement: an update on physiology and current analytical issues","volume":"39","author":"Saleem","year":"2018","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.mehy.2019.02.051_b0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000452906","article-title":"Prolactin: an immunomodulator in health and disease","volume":"48","author":"Savino","year":"2017","journal-title":"Front Horm Res"},{"key":"10.1016\/j.mehy.2019.02.051_b0050","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3389\/fimmu.2017.00720","article-title":"Insight into the endocrine system and the immune system: a review of the inflammatory role of prolactin in rheumatoid arthritis and psoriatic arthritis","volume":"8","author":"Tang","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.mehy.2019.02.051_b0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fimmu.2018.00073","article-title":"Prolactin and auto-immunity","volume":"9","author":"Borba","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.mehy.2019.02.051_b0060","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.exer.2007.08.009","article-title":"Traffic of endogenous, transduced, and endocytosed prolactin in rabbit lacrimal acinar cells","volume":"85","author":"Wang","year":"2007","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.mehy.2019.02.051_b0065","first-page":"216","article-title":"Hypophsectomy-induced regression of female rat lacrimal glands: partial restoration and maintenance by dihydrotestosterone and prolactin","volume":"36","author":"Azzarolo","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.mehy.2019.02.051_b0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1677\/joe.0.0900323","article-title":"Interaction between prolactin and androgens in the accessory sex organs of male mice","volume":"90","author":"Keenan","year":"1981","journal-title":"J Endocrinol"},{"key":"10.1016\/j.mehy.2019.02.051_b0075","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00018-008-8463-x","article-title":"Prolactin inducible protein in cancer, fertility and immunoregulation: structure, function and its clinical implications","volume":"66","author":"Hassan","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.mehy.2019.02.051_b0080","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/dna.2016.3472","article-title":"Prolactin-inducible protein: from breast cancer biomarker to immune modulator \u2013 novel insights from knockout mice","volume":"35","author":"Ihedioha","year":"2016","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.mehy.2019.02.051_b0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.exer.2018.10.015","article-title":"Prolactin-inducible protein is a novel biomarker for keratoconus","volume":"179","author":"Sharif","year":"2018","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.mehy.2019.02.051_b0090","doi-asserted-by":"crossref","DOI":"10.1159\/000487585","article-title":"Proteomic analysis of dacryoliths from patients with or without topical Rebamipide treatment","volume":"3","author":"Mano","year":"2018","journal-title":"Biomed Hub"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718313008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718313008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T10:29:14Z","timestamp":1554892154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987718313008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":18,"alternative-id":["S0306987718313008"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.02.051","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolactin and Prolactin-inducible protein (PIP) in the pathogenesis of primary acquired nasolacrimal duct obstruction (PANDO)","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.02.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}